$KLRA
Kailera Therapeutics, Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
Why is KLRA down today? It is at $16.54 (-3.67%), and our scanner flagged it 35 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment KLRA spikes, and full due diligence on KLRA — key stats, earnings, dilution and insider activity. Free.
Get free $KLRA alerts the moment volume spikes
Our scanner flagged $KLRA 35 times in the last 30 days. Create a free account to track $KLRA, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
Key Stats
- Price
- $16.54
- Change today
- -3.67%
- Previous close
- $17.17
- 52-week range
- $16.39 – $28.23
- Market cap
- $2.23B
- Institutional own.
- 87.57%
- Total held
- 87.6%
- Tradeable float
- 16.1M 12% of shares · after 88% institutions
- Short interest
- 6.6M ▲ +3% vs prior · as of 2026-07-31
- Short % of float
- 41.1%
- Days to cover
- 13.2d
- Avg daily volume
- 805K
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Exchange
- XNAS
- 5m
- 0.0x
- 15m
- 0.1x
- 1h
- 0.1x
- 1D
- 0.3x
Get free KLRA + market alerts in your inbox
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Why is $KLRA down today?
KLRA is one of today's most active names, trading on unusually heavy volume (live price and day move above). Our scanner has fired 1 unusual-volume and momentum alert on KLRA today, peaking at 21.2x its normal volume.
Likely catalystKailera Therapeutics, Inc.: Q2 FY2026 results, three months to Jun 30, 2026, from an SEC filing. Read it →Latest filingSC 13GPassive 5%+ stake disclosedAug 14, 2026 · 10 days agoAnalyst data via Nasdaq. Not investment advice.
Insiders
5 open-market buys0 buys, 0 sells last 3 months (11/0 over 12 months)Show 12 recent transactionsMinimize 12 recent transactions
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Renaud Ronald C Jr Officer | Other | 38K 0.03% of company | n/a | 38K | $200K at $5.25 | Jun 9, 26 |
Kaplan Andrew T. Director | Acquired (grant/award) | +17.86M 13.8% of company | n/a | 17.86M | n/a | Apr 20, 26 |
Kaplan Andrew T. Director | Bought (open market) | +8.40M 6.5% of company | added 47% | 26.26M | $134.4M at $16.00 | Apr 20, 26 |
Bain Capital Life Sciences Investors, Llc Beneficial Owner (10%) | Acquired (grant/award) | +21.02M 16.2% of company | n/a | 21.02M | n/a | Apr 20, 26 |
Bain Capital Life Sciences Investors, Llc Beneficial Owner (10%) | Bought (open market) | +1.56M 1.2% of company | added 7.4% | 22.58M | $25.0M at $16.00 | Apr 20, 26 |
Koppel Adam Director | Acquired (grant/award) | +21.02M 16.2% of company | n/a | 21.02M | n/a | Apr 20, 26 |
Koppel Adam Director | Bought (open market) | +1.56M 1.2% of company | added 7.4% | 22.58M | $25.0M at $16.00 | Apr 20, 26 |
Bain Capital Investors Llc Beneficial Owner (10%) | Acquired (grant/award) | +17.86M 13.8% of company | n/a | 17.86M | n/a | Apr 20, 26 |
Bain Capital Investors Llc Beneficial Owner (10%) | Bought (open market) | +8.40M 6.5% of company | added 47% | 26.26M | $134.4M at $16.00 | Apr 20, 26 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Beneficial Owner (10%) | Acquired (grant/award) | +11.51M 8.9% of company | n/a | 9.48M | n/a | Apr 20, 26 |
Rtw Investments, Lp Beneficial Owner (10%) | Acquired (grant/award) | +10.28M 7.9% of company | n/a | 10.28M | n/a | Apr 20, 26 |
Rtw Investments, Lp Beneficial Owner (10%) | Bought (open market) | +500K 0.4% of company | added 4.9% | 10.78M | $8.0M at $16.00 | Apr 20, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Dilution watch
Recent offeringAt-the-market (ATM) offering active — the company can keep selling new shares into the market over time (ongoing). If $KLRA runs, these filings show who may be positioned to sell new or newly-registered shares into the move.
- 43,750,000 new shares · At-the-market (ATM) program — sells new shares into the market gradually over time · About $700.0M in size · Priced at $16/share
- About $225.0M in size
Sourced from SEC EDGAR filings (last 9 months); terms read straight from the filing text where available. Ongoing = an at-the-market (ATM) program still selling over time or a live shelf, so it can keep diluting; Completed = a one-time priced sale that already finished. A shelf (S-3) stays effective ~3 years. Form type signals dilution capacity, not an exact share count, and we can't confirm how much of a shelf or ATM remains unused. Not investment advice.
$KLRA Sentiment
BullishBlend of news sentiment, today’s move, and community votes. Not investment advice.
$KLRA Activity
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
Stocks similar to KLRA
Comparable names in pharmaceutical preparations, closest in size first.
KLRA stock FAQ
Why is $KLRA down today?
KLRA is one of today's most active names, trading on unusually heavy volume (live price and day move above). Our scanner has fired 1 unusual-volume and momentum alert on KLRA today, peaking at 21.2x its normal volume.
What is the KLRA stock price today?
KLRA last traded at $16.54, down 3.67% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Where can I see live KLRA alerts?
The KLRA Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged KLRA 35 times in the last 30 days.
What exchange is KLRA on?
KLRA (Kailera Therapeutics, Inc. Common Stock) trades on XNAS, with a market cap of about $2.23B in the PHARMACEUTICAL PREPARATIONS sector.
Is KLRA good for day trading?
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge KLRA for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.